Corvus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. 

CEO
Richard A. Miller
CEORichard A. Miller
Employees
31
Employees31
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2014
Founded2014
Employees
31
Employees31

CRVS Key Statistics

Market cap
1.32B
Market cap1.32B
Price-Earnings ratio
-29.53
Price-Earnings ratio-29.53
Dividend yield
Dividend yield
Average volume
1.03M
Average volume1.03M
High today
$16.19
High today$16.19
Low today
$15.38
Low today$15.38
Open price
$15.94
Open price$15.94
Volume
1.40M
Volume1.40M
52 Week high
$26.95
52 Week high$26.95
52 Week low
$2.54
52 Week low$2.54

Stock Snapshot

The current Corvus Pharmaceuticals(CRVS) stock price is $15.80, with a market capitalization of 1.32B. The stock trades at a price-to-earnings (P/E) ratio of -29.53.

On 2026-03-06, Corvus Pharmaceuticals(CRVS) stock moved within a range of $15.38 to $16.19. With shares now at $15.80, the stock is trading +2.7% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 1.4M, compared to an average daily volume of 1.03M.

The stock's 52-week range extends from a low of $2.54 to a high of $26.95.

The stock's 52-week range extends from a low of $2.54 to a high of $26.95.

CRVS News

TipRanks 1d
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch

Corvus Pharmaceuticals Inc. (CRVS) announced an update on their ongoing clinical study. The Phase 2 SIERRA1 study, officially titled “A Phase 2 Multicenter, Ra...

TipRanks 2d
Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:1. Implied volatility suggests the market is anticipating a mov...

Simply Wall St 7d
Assessing Corvus Pharmaceuticals Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data

Advertisement Conference update and pipeline focus Corvus Pharmaceuticals (CRVS) has come into focus after its appearance at the Oppenheimer 36th Annual Healt...

Assessing Corvus Pharmaceuticals Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.